RAPT Therapeutics, Inc (RAPT)

Etorro trading 970x250
RAPT Therapeutics, Inc (RAPT) Logo

About RAPT Therapeutics, Inc

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company’s lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Address: 561 Eccles Avenue, South San Francisco, CA, United States, 94080

RAPT Therapeutics, Inc News and around…

Latest news about RAPT Therapeutics, Inc (RAPT) common stock and company :

RAPT Therapeutics Announces Private Placement Financing of $50 Million
25 May, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced a $50 million private investment in public equity (PIPE) financing from the sale of pre-funded warrants to purchase up to 4 million shares of its common st

What 4 Analyst Ratings Have To Say About RAPT Therapeutics
24 May, 2022 FinancialContent

Analysts have provided the following ratings for RAPT Therapeutics (NASDAQ:RAPT) within the last quarter: Bullish Somewhat ...

RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
23 May, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as

Starbucks And 2 Other Stocks Insiders Are Buying
13 May, 2022 FinancialContent

Although the Dow Jones jumped by more than 400 points on Friday, there were a few notable insider trades. When insiders purchase ...

Rapt Therapeutics (RAPT) Reports Q1 Loss, Tops Revenue Estimates
11 May, 2022 Yahoo! Finance

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -4.55% and 60.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Recap: RAPT Therapeutics Q1 Earnings
11 May, 2022 FinancialContent

RAPT Therapeutics (NASDAQ:RAPT) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what ...

RAPT Therapeutics Reports First Quarter 2022 Financial Results
11 May, 2022 Yahoo! Finance

Company maintains strong cash position of $173.0 millionSOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the quarter ended March 31, 2022. “As we kick off 2022, we continue to make st

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
09 May, 2022 Yahoo! Finance

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -21.47% and 83.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Noteworthy Monday Option Activity: MSTR, RAPT, UI
09 May, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in MicroStrategy Inc. (MSTR), where a total volume of 23,939 contracts has been traded thus far today, a contract volume which is representative of approximately 2.4 million underlying shares (given that every 1 contract represents 100 underlying shares)..

AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Tops Revenue Estimates
05 May, 2022 Yahoo! Finance

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 12.50% and 31.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Stocks That Hit 52-Week Lows On Wednesday
04 May, 2022 FinancialContent

During Wednesday's trading, 435 companies set new 52-week lows. Key Facts About Today's 52-Week Lows: The ...

RAPT Therapeutics Expands Leadership Team with Multiple Key Hires
04 May, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointments of Gwen Carscadden as Chief Human Resources Officer, Jim Farmer as Vice President of Clinical Operations and Shari Geffon as Vice Presiden

Noteworthy Wednesday Option Activity: RAPT, SMCI, USFD
20 Apr, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in RAPT Therapeutics Inc (RAPT), where a total of 1,305 contracts have traded so far, representing approximately 130,500 underlying shares. That amounts to about 75.5% of RAPT's average daily trading volume over the past month of 172,960 shares..

Notable Tuesday Option Activity: GRPN, CASH, RAPT
12 Apr, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Groupon Inc (GRPN), where a total of 7,270 contracts have traded so far, representing approximately 727,000 underlying shares. That amounts to about 103.8% of GRPN's average daily trading volume over the past month of 700,365 shares..

We're Not Very Worried About RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Rate
11 Apr, 2022 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although...

RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis
28 Mar, 2022 Yahoo! Finance

Significant improvement in atopic dermatitis gene signatures in patients treated with RPT193 reported in late-breaking presentation at the American Academy of Dermatology Annual MeetingSOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory disease

RAPT Therapeutics's Return On Capital Employed Insights
14 Mar, 2022 FinancialContent

According to Benzinga Pro data, during Q4, RAPT Therapeutics (NASDAQ:RAPT) posted sales of $756.00 thousand. Earnings were up 3.87%, but ...

RAPT Therapeutics: Q4 Earnings Insights
10 Mar, 2022 FinancialContent

RAPT Therapeutics (NASDAQ:RAPT) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what ...

RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results
10 Mar, 2022 Yahoo! Finance

Company maintains strong cash position of $189.7 millionSOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2021. “2021 was a significant

Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Tops Revenue Estimates
01 Mar, 2022 Yahoo! Finance

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.67% and 71.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
24 Feb, 2022 Yahoo! Finance

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -107.14% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

TUSA's Underlying Holdings Could Mean 17% Gain Potential
11 Feb, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Total US Market AlphaDEX ETF (TUSA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $56.54 per unit.

RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference
09 Feb, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at the 11th Annual SVB Leerink Healthcare Conference on Wedne

State Board Of Administration Of Florida Retiremen Buys Canadian Pacific Railway, VMware Inc, ...
08 Feb, 2022 Yahoo! Finance

Investment company State Board Of Administration Of Florida Retiremen (Current Portfolio) buys Canadian Pacific Railway, VMware Inc, Coterra Energy Inc, Realty Income Corp, Clarivate PLC, sells , , , , during the 3-months ended 2021Q4, according to the most recent filings of the investment company, State Board Of Administration Of Florida Retiremen.

65 Biggest Movers From Yesterday
19 Jan, 2022 FinancialContent

Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co ...

Notable Two Hundred Day Moving Average Cross - RAPT
13 Jan, 2022 FinancialContent

In trading on Thursday, shares of RAPT Therapeutics Inc (RAPT) crossed below their 200 day moving average of $30.20, changing hands as low as $29.82 per share. RAPT Therapeutics Inc shares are currently trading down about 2.1% on the day..

60 Biggest Movers From Yesterday
11 Jan, 2022 FinancialContent

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) ...

RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
04 Jan, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:00 a.

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
09 Dec, 2021 FinancialContent

Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform. BMO ...

Interesting RAPT Put And Call Options For February 2022
06 Dec, 2021 FinancialContent

Investors in RAPT Therapeutics Inc (RAPT) saw new options become available this week, for the February 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 74 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

RAPT Therapeutics, Inc (RAPT) is a NASDAQ Common Stock listed in , ,

970x250